Allurion Technologies (NYSE:ALUR – Get Free Report) and TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.
Profitability
This table compares Allurion Technologies and TriSalus Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Allurion Technologies | -199.96% | N/A | -77.13% |
| TriSalus Life Sciences | -60.85% | N/A | -69.91% |
Earnings & Valuation
This table compares Allurion Technologies and TriSalus Life Sciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Allurion Technologies | $17.21 million | 0.58 | -$7.20 million | ($2.03) | -0.33 |
| TriSalus Life Sciences | $45.15 million | 5.13 | -$39.23 million | ($1.41) | -2.67 |
Allurion Technologies has higher earnings, but lower revenue than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
21.4% of Allurion Technologies shares are held by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are held by institutional investors. 8.1% of Allurion Technologies shares are held by company insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Risk & Volatility
Allurion Technologies has a beta of -0.13, indicating that its share price is 113% less volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Allurion Technologies and TriSalus Life Sciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Allurion Technologies | 1 | 1 | 1 | 0 | 2.00 |
| TriSalus Life Sciences | 1 | 1 | 2 | 0 | 2.25 |
Allurion Technologies presently has a consensus price target of $3.00, suggesting a potential upside of 354.55%. TriSalus Life Sciences has a consensus price target of $7.50, suggesting a potential upside of 98.94%. Given Allurion Technologies’ higher probable upside, research analysts clearly believe Allurion Technologies is more favorable than TriSalus Life Sciences.
Summary
TriSalus Life Sciences beats Allurion Technologies on 9 of the 13 factors compared between the two stocks.
About Allurion Technologies
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
Receive News & Ratings for Allurion Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allurion Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
